Developing strategies for therapeutic angiogenesis: Vascular endothelial growth factor may not be the answer [7]

British Journal of Plastic Surgery

Volumn 56, Issue 3, 2003, Pages 314-

  Clover, A J P ^a   McCarthy, M J ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL MODEL; ENDOTHELIUM CELL; HUMAN; LETTER; NONHUMAN; PLASTIC SURGERY; PRIORITY JOURNAL; TISSUE FLAP; VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 0042173067     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0007-1226(03)00230-3     Document Type: Erratum

References (10)

1. Brindle NP, McCarthy MJ, Bell PR. Angiogenic revascularisation in ischaemic disease: molecular techniques hold promise, though they are still some way off. BMJ 1999;318:1500-1.
2. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
3. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-6.
4. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
5. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
6. Vikkula M, Boon LM, Carraway III KL, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996;87:1181-90.
7. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
8. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-40.
9. Chae JK, Kim I, Lim ST, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 2000;20:2573-8.
10. Lubiatowski P, Gurunluoglu R, Goldman CK, et al. Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. Plast Reconstr Surg 2002;110:149-59.